Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Dose-ranging, Placebo Controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19 (INTEGRIS-ARDS)

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Dose-ranging, Placebo Controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19 (INTEGRIS-ARDS)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bexotegrast (Primary)
  • Indications Acute lung injury; COVID-19 respiratory infection; SARS-CoV-2 acute respiratory disease
  • Focus Adverse reactions
  • Acronyms INTEGRIS-ARDS
  • Sponsors Pliant Therapeutics

    • Most Recent Events

    • 09 Aug 2021 According to a Pliant Therapeutics media release, given the declining number of addressable patients, the company has discontinued enrollment in this trial allowing for resources to be directed toward company's lead indications.
    • 09 Aug 2021 Status changed from recruiting to discontinued according to a Pliant Therapeutics media release.
    • 28 Oct 2020 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top